MX2024004049A - Metodo para producir compuesto o sal farmaceuticamente aceptable del mismo. - Google Patents

Metodo para producir compuesto o sal farmaceuticamente aceptable del mismo.

Info

Publication number
MX2024004049A
MX2024004049A MX2024004049A MX2024004049A MX2024004049A MX 2024004049 A MX2024004049 A MX 2024004049A MX 2024004049 A MX2024004049 A MX 2024004049A MX 2024004049 A MX2024004049 A MX 2024004049A MX 2024004049 A MX2024004049 A MX 2024004049A
Authority
MX
Mexico
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
producing compound
producing
Prior art date
Application number
MX2024004049A
Other languages
English (en)
Spanish (es)
Inventor
Mizuki Kawahira
Ryo MINAMIKAWA
Akira Matsutani
Yuya MAGATA
Shinji Kawanishi
Original Assignee
Ea Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ea Pharma Co Ltd filed Critical Ea Pharma Co Ltd
Publication of MX2024004049A publication Critical patent/MX2024004049A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2024004049A 2021-10-05 2022-10-04 Metodo para producir compuesto o sal farmaceuticamente aceptable del mismo. MX2024004049A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021164171 2021-10-05
PCT/JP2022/037098 WO2023058645A1 (ja) 2021-10-05 2022-10-04 化合物又はその薬学的に許容される塩の製造方法

Publications (1)

Publication Number Publication Date
MX2024004049A true MX2024004049A (es) 2024-04-25

Family

ID=85803498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004049A MX2024004049A (es) 2021-10-05 2022-10-04 Metodo para producir compuesto o sal farmaceuticamente aceptable del mismo.

Country Status (11)

Country Link
US (1) US20240262805A1 (https=)
EP (1) EP4414362A4 (https=)
JP (1) JPWO2023058645A1 (https=)
KR (1) KR20240073943A (https=)
CN (1) CN118055925A (https=)
AU (1) AU2022361862A1 (https=)
CA (1) CA3234498A1 (https=)
IL (1) IL311879A (https=)
MX (1) MX2024004049A (https=)
TW (1) TW202330490A (https=)
WO (1) WO2023058645A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116947658B (zh) * 2023-07-28 2025-10-28 南通华祥医药科技有限公司 一种1-氨基-2-甲基-2-丙醇的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3269772B1 (en) * 2015-03-10 2020-11-11 Unimatec Co., Ltd. Fluorine-containing boric acid/pvb composite
ES2856125T3 (es) 2016-02-05 2021-09-27 Ea Pharma Co Ltd Derivado de sulfonamida y composición farmacéutica que contiene la misma
TW201731824A (zh) * 2016-02-05 2017-09-16 Ea Pharma Co Ltd α4β7整合蛋白抑制劑
JP2019031449A (ja) * 2017-08-04 2019-02-28 Eaファーマ株式会社 スルホンアミド誘導体及びそれを含有する医薬組成物

Also Published As

Publication number Publication date
EP4414362A4 (en) 2025-09-03
IL311879A (en) 2024-06-01
WO2023058645A1 (ja) 2023-04-13
CA3234498A1 (en) 2023-04-13
AU2022361862A1 (en) 2024-04-18
JPWO2023058645A1 (https=) 2023-04-13
KR20240073943A (ko) 2024-05-27
CN118055925A (zh) 2024-05-17
US20240262805A1 (en) 2024-08-08
TW202330490A (zh) 2023-08-01
EP4414362A1 (en) 2024-08-14

Similar Documents

Publication Publication Date Title
CL2021000783A1 (es) Proceso de fabricación de un compuesto para la inhibición de la actividad de shp2
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
ECSP22050936A (es) Compuestos tric?clicos sustituidos
GR20010100131A (el) Μεθοδος για την παρασκευη καθαρης κιταλοπραμης
JP2010106029A5 (https=)
MX2024004049A (es) Metodo para producir compuesto o sal farmaceuticamente aceptable del mismo.
AR126196A1 (es) Proceso para preparar inhibidores de egfr
DOP2025000146A (es) Compuesto quimérico protac, método de preparación del mismo y uso del mismo
CO2024013702A2 (es) Derivados de pirido-[3,4-d]piridazina amina útiles como derivados de nlrp3
DOP2024000146A (es) Inhibidores de parp7
AR109669A1 (es) Proceso para preparar 2-exo-(2-metilbenciloxi)-1-metil-4-isopropil-7-oxabiciclo[2.2.1]heptano
FR3060000B1 (fr) Procede pour eviter le depot de polymeres dans un procede de purification d'acide (meth)acrylique.
DOP2025000009A (es) Inhibidores de acc novedosos
AR131372A1 (es) Procedimiento para la preparación de un derivado de quinazolinona
AR124966A1 (es) Un proceso para la preparación de sulfentrazona con compatibilidad con mezcla en tanque
RU2014126489A (ru) Способ извлечения налмефена гидрохлорида
AR128279A1 (es) Nuevos derivados de bencimidazol piridina
AR123965A1 (es) Proceso de purificación de pleuromutilinas
MX2024013227A (es) Proceso para la produccion de intermediarios de estetrol
Sims Decarboxylation of Cyclopropylacetic Acid Derivatives. A New Synthetic Method
Hanafusa et al. Introduction of an Angular Methyl Group by Decarboxylative Cyclopropane Ring Opening1
PE20251279A1 (es) Metodos de flujo continuo para producir manosa-1-fosfato, polimorfos de manosa-1-fosfato y composiciones y usos relacionados con los mismos
AR126600A1 (es) Compuestos novedosos de estireno y un proceso para la preparación de los mismos
AR035073A1 (es) Un procedimiento para preparar un derivado de distamicina y un compuesto intermedio
ES2309416T3 (es) Procedimiento estereoselectivo para la preparacion de clopidogrel.